PRN: 'World Drug Revenues for Treating Inflammatory Bowel Diseases Will Reach $6.9bn in 2015' Says Latest Visiongain Report

26/lug/2011 12.01.23 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

'World Drug Revenues for Treating Inflammatory Bowel Diseases Will Reach $6.9bn in 2015' Says Latest Visiongain Report

 
[26-July-2011]
 

LONDON, July 26, 2011 /PRNewswire/ --

 

http://www.visiongain.com/Report/650/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021


A new report by visiongain, a London-based business information company, predicts that world drug revenues for treating inflammatory bowel diseases will reach $6.9bn in 2015. The IBD drug market generated revenues of $5bn in 2010, according to Inflammatory Bowel Diseases: World Drug Market 2011-2021, published in July 2011.

Inflammatory bowel diseases (IBD) are autoimmune disorders in which parts of the intestinal tract experience severe and chronic inflammation. The main forms are Crohn's disease and ulcerative colitis. Inflammatory bowel diseases damage the bowel irreversibly, causing serious discomfort and difficulties for patients. Surgery and drugs have improved patients' lives.

Diya Lahiri, pharmaceutical industry analyst, said: "The world IBD treatments market will benefit from the entry of new technologies, products and companies this decade. There are prominent needs in the IBD treatment market, the most important being the development of drugs that are disease modifying rather than only symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers better understand IBD."

Visiongain forecasts that the IBD drug market will expand steadily to 2021. The future of the market appears promising, with increasing demand for IBD treatments. There is a strong R&D pipeline for treating inflammatory bowel diseases. The prospect of new, more-effective drugs, including biologics and intestinal anti-inflammatory agents (IAIs), will help this market to grow. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry

For more information about this report please click on:

http://www.visiongain.com/Report/650/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021

Table of Contents
1. Executive Summary
1.1 Inflammatory Bowel Disease Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to the Inflammatory Bowel Disease Market
2.1 Definition of Inflammatory Bowel Disease (IBD)
2.2 Types of IBD
2.3 Signs, Symptoms and Associated Conditions
2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations, Toxic Megacolon
2.3.2 Pyoderma Gangrenosum
2.3.3 Primary Sclerosing Cholagitis
2.3.4 Malnutrition, Poor Nutrient Absorption and Stunting
2.4 Ulcerative Colitis
2.5 Crohn's Disease
2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis
2.7 What Causes Inflammatory Bowel Disease?
2.7.1 Genetic Factors
2.7.2 Environmental Factors
2.8 How Common is Inflammatory Bowel Disease?
2.8.1 Geographical Variations in Rates of IBD
2.9 Socioeconomic Costs of IBD
2.9.1 The Individual Cost of IBD

3. Treatments for Inflammatory Bowel Diseases
3.1 Treatment Goals
3.2 Drug Classes Used in IBD Treatment
3.2.1 Aminosalicylates
3.2.2 Corticosteroids
3.2.3 Immunomodulators
3.2.4 Monoclonal Antibodies
3.3 Surgery
3.3.1 Surgery for Ulcerative Colitis
3.3.2 Surgery for Crohn's Disease
3.4 Alternative Treatments
3.4.1 Faecal Bateriotherapy and Pre/Probiotics
3.4.2 Helminthic Therapy
3.4.3 Complementary Medicine
3.5 Treatment Protocol
3.5.1 Recent Trial Data

4. The World Inflammatory Bowel Disease Market, 2011-2021
4.1 Non-Biological Drugs
4.1.1 IBD-Specific Drugs (Intestinal Anti-Inflammatories)
4.1.2 Drugs Not Specific to IBD
4.2 Biological Drugs
4.3 Total IBD Market
4.4 Market Shares by Disease Type
4.5 Market Forecast: World Inflammatory Bowel Disease Sales, 2011-2021
4.6 Market Forecast: World Sales by Disease Type, 2011-2021
4.7 Market Forecast: World Sales by Therapy Type, 2011-2021

5. Market Prospects for Leading IBD Drugs, 2011-2021
5.1 Intestinal Anti-Inflammatory Drugs (IAIs/Non Biological Drugs)
5.2 Asacol (Mesalazine) - Warner Chilcott
5.2.1 Asacol: Information
5.2.2 Asacol Forecast and Analysis, 2011-2021
5.3 Pentasa (mesalazine) - Shire/Ferring
5.3.1 Pentasa: Information
5.3.2 Pentasa: Forecast and Analysis, 2011-2021
5.4 Entocort (budenoside) - AstraZeneca, Prometheus
5.4.1 Entocort: Information
5.4.2 Entocort: Forecast and Analysis, 2011-2021
5.5 Lialda (mesalazine) - Shire
5.5.1 Lialda: Information
5.5.2 Lialda: Forecast and Analysis, 2011-2021
5.6 Salofalk (mesalazine) - Dr. Falk
5.6.1 Salofalk: Information
5.6.2 Salofalk: Forecast and Analysis, 2011-2021
5.7 Other IAIs
5.8 Biological Drugs Used to Treat IBD
5.9 Remicade (infliximab) - Merck & Co., Schering-Plough, Johnson & Johnson
5.9.1 Remicade: Information
5.9.2 Remicade: Forecast and Analysis, 2011-2021
5.10 Humira (adalimumab) - Abbott
5.10.1 Humira: information
5.10.2 Humira: Forecast and Analysis, 2011-2021
5.11 Cimzia (certolizumab pegol) - UCB
5.11.1 Cimzia: Information
5.11.2 Cimzia: Forecast and Analysis, 2011-2021
5.12 Tysabri (natalizumab) - Biogen Idec/Elan
5.12.1 Tysabri: Information
5.12.2 Tysabri: Forecast and Analysis, 2011-2021

6. The R&D Pipeline for Inflammatory Bowel Disease, 2011-2021
6.1 Monoclonal Antibodies
6.1.1 HuZAF (fontolizumab) - Biogen Idec
6.1.2 Stelara (uskinamab) - Johnson & Johnson
6.1.3 Vedolizumab (MLN02) - Takeda
6.1.4 Simponi (golimumab) - Johnson & Johnson
6.2 Small Molecules
6.2.1 Tetomilast - Otsuka
6.2.2 Firategrast -GlaxoSmithKline
6.3 Antibiotics
6.3.1 Rifaxamin - Salix Pharmaceuticals
6.3.2 Myconda - Giaconda
6.4 Nicotine and Buproprion
6.5 Alicaforsen - Isis
6.6 Alequel - Enzo
6.7 MAP Vaccine
6.8 Autologous Stem Cell Transplantation for Crohn's Disease
6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Market, 2011-2021
7.1 SWOT Analysis of the IBD Market
7.2 Market Drivers
7.2.1 Increasing Disease Incidence
7.2.2 Better Diagnosis
7.2.3 Nature of the Disease
7.2.4 Delivery Systems
7.2.5 Biological Drugs
7.3 Market Restraints
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance
7.3.3 Limits of Biologics
7.3.4 A Cure or Vaccine

8. Leading National Markets for Inflammatory Bowel Disease Treatments, 2011-2021
8.1 Leading National Markets for IBD, 2011-2021
8.2 The US IBD Market: Forecast and Outlook, 2011-2021
8.3 The Japanese IBD Market: Forecast and Outlook, 2011-2021
8.4 Leading European IBD Markets: Forecasts and Outlook, 2011-2021
8.4.1 The German IBD Market, 2011-2021
8.4.2 The French IBD Market, 2011-2021
8.4.3 The Italian IBD Market, 2011-2021
8.4.4 The Spanish IBD Market, 2011-2021
8.4.5 The UK IBD Market, 2011-2021
8.5 Top 5 EU Markets for IBD Drugs, 2011-2021
8.6 IBD Drugs in Emerging Markets
8.6.1 Chinese IBD Market: Forecast and Outlook, 2011-2021
8.6.2 Indian IBD Market: Forecast and Outlook, 2011-2021
8.7 IBD Revenues from the Two Leading Emerging Markets, 2011-2021
8.8 Revenues for IBD Drugs in the Rest of the World: Forecast and Outlook, 2011-2021
8.9 Global IBD Market by Region, 2010

9. Leading Companies in the Industry and Market
9.1 The Largest Companies by Revenue in the Intestinal Anti-Inflammatory Market
9.2 Warner Chilcott
9.3 Shire Pharmaceuticals Group
9.4 Prometheus Laboratories
9.5 Ferring Pharmaceuticals
9.6 Kyorin Pharmaceutical Co.

10. Research Interviews from Our Survey
10.1 Professor John Hermon-Taylor, King's College London
10.1.1 The Significance of MAP in Crohn's
10.1.2 Rising Incidence of IBD
10.1.3 Defining IBD
10.1.4 Timeframe of MAP Vaccine
10.1.5 Antibiotic Activity of Other Crohn's Treatments
10.1.6 Alternative Treatments
10.1.7 Ethics of Crohn's Drug Development
10.1.8 The Impact of a Vaccine on the Market
10.1.9 On Claims that MAP is Not Implicated in CD
10.2 Marco Greco, Chairman, European Federation of Crohn's and Ulcerative Colitis Associations
10.2.1 Public Awareness of IBD
10.2.2 The Differences between European Countries
10.2.3 Drug Companies and Their Involvement in Awareness Campaigns
10.2.4 Unmet Medical Needs
10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP
10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 The Potential and Future of Myoconda

11. Conclusions
11.1 IBD Market to Grow from 2011 to 2021
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatments
11.5 Future IBD Treatments: R&D Efforts Promising
11.6 The IBD Sector: Looking to the Future Confidently

List of Tables
Table 2.1 World Incidence Rates for IBD, 2011
Table 2.2 Geographical Variations in the Incidence of IBD, 2010
Table 2.3 Misdiagnosis of IBD in Developing Countries, 2011
Table 3.1 Drug Types Used to treat IBD, 2011
Table 3.2 Drugs Used to Treat IBD, 2011
Table 4.1 Total IBD Market Forecast with Main Submarkets ($m), 2010-2021
Table 4.2 Global IBD Market Forecast ($m), 2010-2021
Table 4.3 World IBD Market Forecasts by Disease ($m), 2010-2021
Table 4.4 World IBD Market Shares (%) and Revenues ($m) by Disease Type, 2010, 2015 and 2021
Table 4.5 IBD Drug Market Forecasts ($m) by Therapy Type, 2010-2021
Table 5.1 Top 5 IAI Drugs ($m), 2010
Table 5.2 World Asacol Revenue Forecast ($m), 2010-2021
Table 5.3 World Pentasa Revenue Forecast ($m), 2010-2021
Table 5.4 World Entocort Revenue Forecast ($m), 2010-2021
Table 5.5 World Lialda Revenue Forecast ($m), 2010-2021
Table 5.6 World Salofalk Revenue Forecast ($m), 2010-2021
Table 5.7 Market Forecast for top IAI Drugs ($m), 2010-2021
Table 5.8 World Remicade Revenue Forecast ($m), 2010-2021
Table 5.9 World Humira Revenue Forecast ($m), 2010-2021
Table 5.10 World Cimzia Revenue Forecast ($m), 2010-2021
Table 5.11 World Tysabri Revenue Forecast ($m), 2010-2021
Table 5.12 Market Forecasts ($m) for Top Biological IBD Drugs, 2010-2021
Table 5.13 World IBD Drug Market Forecasts ($m) by Drug Class, 2010-2021
Table 6.1 R&D Pipeline for Anti-IBD Products, 2011
Table 7.1 SWOT Analysis of the World Inflammatory Bowel Disease Drug Market, 2011-2021
Table 8.1 Leading National Markets for IBD Treatments: Revenues ($m) and Market Shares (%), 2010, 2015 and 2021
Table 8.2 US IBD Drug Market Forecast ($m), 2010-2021
Table 8.3 Japanese IBD Drug Market Forecast ($m), 2010-2021
Table 8.4 German IBD Drug Market Forecast ($m), 2010-2021
Table 8.5 French IBD Drug Market Forecast ($m), 2010-2021
Table 8.6 Italian IBD Drug Market Forecast ($m), 2010-2021
Table 8.7 Spanish IBD Drug Market Forecast ($m), 2010-2021
Table 8.8 UK IBD Drug Market Forecast, ($m), 2010-2021
Table 8.9 IBD Drug Market in Top 5 EU Countries ($m), 2010-2021
Table 8.10 Chinese IBD Drug Market Forecast ($m), 2010-2021
Table 8.11 Indian IBD Drug Market Forecast ($m), 2010-2021
Table 8.12 IBD Drug Markets ($m) in the Two Leading Emerging Countries, 2010-2021
Table 8.13 IBD Drug Market in the Rest of the World ($m), 2010-2021
Table 8.14 Global IBD Market by Region: Revenues ($m) and Market Shares (%), 2010
Table 8.15 Leading National Market Forecasts for IBD Drugs ($m), 2010-2021
Table 9.1 Top Three Companies for IAIs: Revenues ($m) and Market Shares (%), 2010
Table 9.2 Warner Chilcott IBD Revenues ($m), 2010
Table 9.3 Shire Pharmaceuticals IBD Revenues ($m), 2010
Table 9.4 Prometheus Laboratories IBD Revenues ($m), 2010
Table 9.5 Diagnostic Tests for IBD Offered by Prometheus, 2011

List of Figures
Figure 2.1 Geographical Variations in the Incidence of IBD, 2010
Figure 3.1 Treatment Protocol for IBD, 2011
Figure 4.1 World IBD Drug Market Forecast ($m), 2010-2021
Figure 4.2 Crohn's Disease Market Forecast ($m), 2010-2021
Figure 4.3 Ulcerative Colitis Market Forecast ($m), 2010-2021
Figure 4.4 CD and UC Market Forecasts ($m), 2010-2021
Figure 4.5 UC and CD Market Shares (%), 2010
Figure 4.6 UC and CD Market Shares (%), 2015
Figure 4.7 UC and CD Market Shares (%), 2021
Figure 4.8 IBD Market Forecasts ($m) by Therapy Type, 2010-2021
Figure 4.9 IBD Drug Market Shares (%) By Therapy Type, 2010-2021
Figure 5.1 World Asacol Revenue Forecast ($m), 2010-2021
Figure 5.2 World Pentasa Revenue Forecast ($m), 2010-2021
Figure 5.3 World Entocort Revenue Forecast ($m), 2010-2021
Figure 5.4 World Lialda Revenue Forecast ($m), 2010-2021
Figure 5.5 World Salofalk Revenue Forecast ($m), 2010-2021
Figure 5.6 Market Forecast for Top IAI Drugs ($m), 2010-2021
Figure 5.7 World Remicade Revenue Forecast ($m), 2010-2021
Figure 5.8 World Humira Revenue Forecast ($m), 2010-2021
Figure 5.9 World Cimzia Revenue Forecast ($m), 2010-2021
Figure 5.10 World Tysabri Revenue Forecast ($m), 2010-2021
Figure 5.11 Market Forecasts for Top Biological IBD Drugs ($m), 2010-2021
Figure 8.1 National Market Shares (%), 2010
Figure 8.2 National Market Shares (%), 2015
Figure 8.3 National Market Shares (%), 2021
Figure 8.4 US IBD Drug Market Forecast ($m), 2010-2021
Figure 8.5 Japanese IBD Drug Market Forecast ($m), 2010-2021
Figure 8.6 US and Japanese IBD Drug Market Forecasts ($m), 2010-2021
Figure 8.7 IBD Drug Sales ($m) in Top 5 EU Countries, 2010-2021
Figure 8.8 IBD Drug Markets ($m) in the Two Leading Emerging Countries, 2010-2021
Figure 8.9 IBD Drug Market in the Rest of the World ($m), 2010-2021
Figure 8.10 Global IVD Market Shares (%) by Region, 2010
Figure 9.1 Top 3 Companies for IAIs: Market Shares (%), 2010 


Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.  

For an exec summary please contact:
Sara Peerun
Email: Sara.peerun@visiongainglobal.com
Tel: +44(0)207-336-6100
Web: http://www.visiongain.com


blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl